Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley Sells 3,300 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $358.15, for a total transaction of $1,181,895.00. Following the completion of the sale, the director now owns 275,916 shares in the company, valued at $98,819,315.40. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jay T. Flatley also recently made the following trade(s):

  • On Wednesday, April 24th, Jay T. Flatley sold 3,300 shares of Illumina stock. The stock was sold at an average price of $321.96, for a total transaction of $1,062,468.00.

Shares of NASDAQ:ILMN traded down $5.35 during trading on Friday, reaching $293.20. The company had a trading volume of 1,733,832 shares, compared to its average volume of 1,492,584. The company has a fifty day moving average price of $342.44. The stock has a market cap of $43.10 billion, a PE ratio of 51.26, a P/E/G ratio of 2.56 and a beta of 1.15. Illumina, Inc. has a 12 month low of $268.62 and a 12 month high of $380.76. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million for the quarter, compared to analyst estimates of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.45 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 6.34 EPS for the current year.

A number of institutional investors have recently made changes to their positions in ILMN. Norges Bank bought a new stake in Illumina in the 4th quarter worth $514,627,000. Thoroughbred Financial Services LLC lifted its position in shares of Illumina by 38,516.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after purchasing an additional 873,560 shares during the period. American Century Companies Inc. lifted its position in shares of Illumina by 107.1% in the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after purchasing an additional 421,953 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Illumina by 362.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 433,566 shares of the life sciences company’s stock worth $130,039,000 after purchasing an additional 339,908 shares during the period. Finally, MERIAN GLOBAL INVESTORS UK Ltd lifted its position in shares of Illumina by 841.1% in the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 269,170 shares of the life sciences company’s stock worth $83,628,000 after purchasing an additional 240,569 shares during the period. 89.81% of the stock is currently owned by institutional investors and hedge funds.

ILMN has been the topic of several recent analyst reports. Wolfe Research initiated coverage on shares of Waters in a research note on Thursday, May 30th. They issued an “underperform” rating on the stock. Bank of America set a $80.00 target price on shares of Colgate-Palmolive and gave the stock a “buy” rating in a research note on Friday, July 12th. Cowen increased their target price on shares of Solaredge Technologies from $65.00 to $74.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. Deutsche Bank increased their price target on shares of Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a report on Friday, July 12th. Finally, ValuEngine lowered shares of Vereit from a “buy” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $338.69.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Call Option

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.